The erythropoietin receptor in normal and cancer tissues

Critical Reviews in Oncology/Hematology

Volumn 67, Issue 1, 2008, Pages 39-61

  Jelkmann, Wolfgang ^a   Bohlius, Julia ^b   Hallek, Michael ^b   Sytkowski, Arthur J ^c  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anemia; Cancer; EPO receptor; Erythropoiesis stimulating agents

Indexed keywords

ABSEAMED; BINOCRIT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; EPIRUBICIN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FLUOROURACIL; HEXAL; HYDROXYUREA; IRON; MIRCERA; MITOMYCIN C; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; RETACRIT; SILAPO;

ANEMIA; ANGIOGENESIS; BREAST CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CLINICAL TRIAL; COLON CARCINOMA; DRUG WITHDRAWAL; ENDOTHELIUM CELL; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; HEAD AND NECK TUMOR; HUMAN; IRON THERAPY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NONHUMAN; OVARY CANCER; PERIPHERAL NERVOUS SYSTEM; PHOSPHORYLATION; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TREATMENT DURATION; TUMOR BIOPSY; TUMOR GROWTH; XENOGRAFT;

ANIMALS; CLINICAL TRIALS AS TOPIC; HEMATINICS; HUMANS; NEOPLASMS; RECEPTORS, ERYTHROPOIETIN; SIGNAL TRANSDUCTION;

EID: 44649130690     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.03.006     Document Type: Review

References (311)

1. Hodges V.M., Rainey S., Lappin T.R., and Maxwell A.P. Pathophysiology of anemia and erythrocytosis. Crit Rev Oncol Hematol 64 (2007) 139-158
2. Brines M., and Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 70 (2006) 246-250
3. Sytkowski A.J. Does erythropoietin have a dark side? Epo signaling and cancer cells. Sci STKE 2007 (2007) e38
4. Lappin T.R., Maxwell A.P., and Johnston P.G. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia. Oncologist 12 (2007) 362-365
5. Miyake T., Kung C.K., and Goldwasser E. Purification of human erythropoietin. J Biol Chem 252 (1977) 5558-5564
6. Krantz S.B., and Goldwasser E. Specific binding of erythropoietin to spleen cells infected with the anemia strain of Friend virus. Proc Natl Acad Sci USA 81 (1984) 7574-7578
7. Sawyer S.T., Krantz S.B., and Luna J. Identification of the receptor for erythropoietin by cross-linking to Friend virus-infected erythroid cells. Proc Natl Acad Sci USA 84 (1987) 3690-3694
8. Sawyer S.T., Krantz S.B., and Goldwasser E. Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. J Biol Chem 262 (1987) 5554-5562
9. Fraser J.K., Lin F.K., and Berridge M.V. Expression of high affinity receptors for erythropoietin on human bone marrow cells and on the human erythroleukemic cell line. HEL. Exp Hematol 16 (1988) 836-842
10. Broudy V.C., Lin N., Egrie J., et al. Identification of the receptor for erythropoietin on human and murine erythroleukemia cells and modulation by phorbol ester and dimethyl sulfoxide. Proc Natl Acad Sci USA 85 (1988) 6513-6517
11. Sawada K., Krantz S.B., Sawyer S.T., and Civin C.I. Quantitation of specific binding of erythropoietin to human erythroid colony-forming cells. J Cell Physiol 137 (1988) 337-345
12. Hitomi K., Fujita K., Sasaki R., et al. Erythropoietin receptor of a human leukemic cell line with erythroid characteristics. Biochem Biophys Res Commun 154 (1988) 902-909
13. Mayeux P., Billat C., and Jacquot R. Murine erythroleukaemia cells (Friend cells) possess high-affinity binding sites for erythropoietin. FEBS Lett 211 (1987) 229-233
14. Noguchi T., Fukumoto H., Mishina Y., and Obinata M. Factors controlling induction of commitment of murine erythroleukemia (TSA8) cells to CFU-E (colony forming unit-erythroid). Development 101 (1987) 169-174
15. Nagao M., Matsumoto S., Masuda S., and Sasaki R. Effect of tunicamycin treatment on ligand binding to the erythropoietin receptor: conversion from two classes of binding sites to a single class. Blood 81 (1993) 2503-2510
16. Tojo A., Fukamachi H., Kasuga M., Urabe A., and Takaku F. Identification of erythropoietin receptors on fetal liver erythroid cells. Biochem Biophys Res Commun 148 (1987) 443-448
17. Todokoro K., Kanazawa S., Amanuma H., and Ikawa Y. Characterization of erythropoietin receptor on erythropoietin-unresponsive mouse erythroleukemia cells. Biochim Biophys Acta 943 (1988) 326-330
18. Sawyer S.T. The two proteins of the erythropoietin receptor are structurally similar. J Biol Chem 264 (1989) 13343-13347
19. McCaffery P.J., Fraser J.K., Lin F.K., and Berridge M.V. Subunit structure of the erythropoietin receptor. J Biol Chem 264 (1989) 10507-10512
20. de Both N.J., Vermey M., van't H.E., et al. A new erythroid cell line induced by Rauscher murine leukaemia virus. Nature 272 (1978) 626-628
21. Sytkowski A.J., Salvado A.J., Smith G.M., McIntyre C.J., and deBoth N.J. Erythroid differentiation of clonal Rauscher erythroleukemia cells in response to erythropoietin or dimethyl sulfoxide. Science 210 (1980) 74-76
22. Chern Y., Yonekura S., and Sytkowski A.J. Potentiation of the erythropoietin response by dimethyl sulfoxide priming of erythroleukemia cells: evidence for interaction of two signaling pathways. Blood 76 (1990) 2204-2209
23. Yonekura S., Chern Y., Donahue K.A., Feldman L., Vanasse G.J., and Sytkowski A.J. Erythropoietin receptors induced by dimethyl sulfoxide exhibit positive cooperativity associated with an amplified biologic response. Proc Natl Acad Sci USA 88 (1991) 2535-2539
24. D'Andrea A.D., Lodish H.F., and Wong G.G. Expression cloning of the murine erythropoietin receptor. Cell 57 (1989) 277-285
25. Jones S.S., D'Andrea A.D., Haines L.L., and Wong G.G. Human erythropoietin receptor: cloning, expression, and biologic characterization. Blood 76 (1990) 31-35
26. Budarf M., Huebner K., Emanuel B., et al. Assignment of the erythropoietin receptor (EPOR) gene to mouse chromosome 9 and human chromosome 19. Genomics 8 (1990) 575-578
27. Maouche L., Tournamille C., Hattab C., Boffa G., Cartron J.P., and Chretien S. Cloning of the gene encoding the human erythropoietin receptor. Blood 78 (1991) 2557-2563
28. Noguchi C.T., Bae K.S., Chin K., Wada Y., Schechter A.N., and Hankins W.D. Cloning of the human erythropoietin receptor gene. Blood 78 (1991) 2548-2556
29. Penny L.A., and Forget B.G. Genomic organization of the human erythropoietin receptor gene. Genomics 11 (1991) 974-980
30. Wickrema A., Krantz S.B., Winkelmann J.C., and Bondurant M.C. Differentiation and erythropoietin receptor gene expression in human erythroid progenitor cells. Blood 80 (1992) 1940-1949
31. Chin K., Yu X., Beleslin-Cokic B., et al. Production and processing of erythropoietin receptor transcripts in brain. Mol Brain Res 81 (2000) 29-42
32. Sato T., Watanabe S., Ishii E., Tsuji K., and Nakahata T. Induction of the erythropoietin receptor gene and acquisition of responsiveness to erythropoietin by stem cell factor in HML/SE, a human leukemic cell line. J Biol Chem 273 (1998) 16921-16926
33. Winter S.S., Howard T., and Ware R.E. Regulation of expression of the human erythropoietin receptor gene. Blood Cells Mol Dis 22 (1996) 214-224
34. Taniguchi S., Dai C.H., Price J.O., and Krantz S.B. Interferon gamma downregulates stem cell factor and erythropoietin receptors but not insulin-like growth factor-I receptors in human erythroid colony-forming cells. Blood 90 (1997) 2244-2252
35. Zon L.I., Youssoufian H., Mather C., Lodish H.F., and Orkin S.H. Activation of the erythropoietin receptor promoter by transcription factor GATA-1. Proc Natl Acad Sci USA 88 (1991) 10638-10641
36. Maouche L., Lucien N., Cartron J.P., and Chretien S. A CCACC motif mediates negative transcriptional regulation of the human erythropoietin receptor. Eur J Biochem 233 (1995) 793-799
37. Hosoi T., Sawyer S.T., and Krantz S.B. Photoaffinity labeling of the erythropoietin receptor and its identification in a ligand-free form. Biochemistry 30 (1991) 329-335
38. Bailey S.C., Feldman L., Romanowski R.R., Davis K.L., and Sytkowski A.J. Antipeptide antibodies as probes of the recombinant and endogenous murine erythropoietin receptors. Exp Hematol 21 (1993) 1535-1543
39. D'Andrea A.D., Fasman G.D., and Lodish H.F. Erythropoietin receptor and interleukin-2 receptor beta chain: a new receptor family. Cell 58 (1989) 1023-1024
40. Bazan J.F. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 87 (1990) 6934-6938
41. Ihle J.N., and Kerr I.M. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet 11 (1995) 69-74
42. Bazan J.F. A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain. Biochem Biophys Res Commun 164 (1989) 788-795
43. Ihle J.N., Thierfelder W., Teglund S., et al. Signaling by the cytokine receptor superfamily. Ann NY Acad Sci 865 (1998) 1-9
44. Quelle D.E., Quelle F.W., and Wojchowski D.M. Mutations in the WSAWSE and cytosolic domains of the erythropoietin receptor affect signal transduction and ligand binding and internalization. Mol Cell Biol 12 (1992) 4553-4561
45. Yoshimura A., Zimmers T., Neumann D., Longmore G., Yoshimura Y., and Lodish H.F. Mutations in the Trp-Ser-X-Trp-Ser motif of the erythropoietin receptor abolish processing, ligand binding, and activation of the receptor. J Biol Chem 267 (1992) 11619-11625
46. Murakami M., Narazaki M., Hibi M., et al. Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. Proc Natl Acad Sci USA 88 (1991) 11349-11353
47. O'Neal K.D., and Yu-Lee L.Y. The proline-rich motif (PRM): a novel feature of the cytokine/hematopoietin receptor superfamily. Lymphokine Cytokine Res 12 (1993) 309-312
48. VanderKuur J.A., Wang X., Zhang L., et al. Domains of the growth hormone receptor required for association and activation of JAK2 tyrosine kinase. J Biol Chem 269 (1994) 21709-21717
49. Syed R.S., Reid S.W., Li C., et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 395 (1998) 511-516
50. Philo J.S., Aoki K.H., Arakawa T., Narhi L.O., and Wen J. Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. Biochemistry 35 (1996) 1681-1691
51. de Vos A.M., Ultsch M., and Kossiakoff A.A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255 (1992) 306-312
52. Witthuhn B.A., Quelle F.W., Silvennoinen O., et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74 (1993) 227-236
53. Tanner J.W., Chen W., Young R.L., Longmore G.D., and Shaw A.S. The conserved box 1 motif of cytokine receptors is required for association with JAK kinases. J Biol Chem 270 (1995) 6523-6530
54. Constantinescu S.N., Huang L.J., Nam H., and Lodish H.F. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. Mol Cell 7 (2001) 377-385
55. Miller C.P., Liu Z.Y., Noguchi C.T., and Wojchowski D.M. A minimal cytoplasmic subdomain of the erythropoietin receptor mediates erythroid and megakaryocytic cell development. Blood 94 (1999) 3381-3387
56. Hilton C.J., and Berridge M.V. Conserved region of the cytoplasmic domain is not essential for erythropoietin-dependent growth. Growth Factors 12 (1995) 263-276
57. Zhang M.Y., Barber D.L., Alessi D.R., et al. A minimal cytoplasmic subdomain of the erythropoietin receptor mediates p70 S6 kinase phosphorylation. Exp Hematol 29 (2001) 432-440
58. Chin H., Arai A., Wakao H., Kamiyama R., Miyasaka N., and Miura O. Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway. Blood 91 (1998) 3734-3745
59. Machide M., Mano H., and Todokoro K. Interleukin 3 and erythropoietin induce association of Vav with Tec kinase through Tec homology domain. Oncogene 11 (1995) 619-625
60. Miura O., Nakamura N., Quelle F.W., Witthuhn B.A., Ihle J.N., and Aoki N. Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo. Blood 84 (1994) 1501-1507
61. Debeljak N, Sytkowski AJ. EpoR. UCSD-Nature Molecule Pages 2007;A000863.
62. Damen J.E., Mui A.L., Puil L., Pawson T., and Krystal G. Phosphatidylinositol 3-kinase associates, via its Src homology 2 domains, with the activated erythropoietin receptor. Blood 81 (1993) 3204-3210
63. Chin H., Nakamura N., Kamiyama R., Miyasaka N., Ihle J.N., and Miura O. Physical and functional interactions between Stat5 and the tyrosine-phosphorylated receptors for erythropoietin and interleukin-3. Blood 88 (1996) 4415-4425
64. Gobert S., Chretien S., Gouilleux F., et al. Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STAT5 activation. EMBO J 15 (1996) 2434-2441
65. Barber D.L., Beattie B.K., Mason J.M., et al. A common epitope is shared by activated signal transducer and activator of transcription-5 (STAT5) and the phosphorylated erythropoietin receptor: implications for the docking model of STAT activation. Blood 97 (2001) 2230-2237
66. Sasaki A., Yasukawa H., Shouda T., Kitamura T., Dikic I., and Yoshimura A. CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem 275 (2000) 29338-29347
67. Fichelson S., Chretien S., Rokicka-Piotrowicz M., et al. Tyrosine residues of the erythropoietin receptor are dispensable for erythroid differentiation of human CD34+ progenitors. Biochem Biophys Res Commun 256 (1999) 685-691
68. 2+ channels: activation by phospholipase C-gamma 1. Kidney Int 53 (1998) 1259-1268
69. Torti M., Marti K.B., Altschuler D., Yamamoto K., and Lapetina E.G. Erythropoietin induces p21ras activation and p120GAP tyrosine phosphorylation in human erythroleukemia cells. J Biol Chem 267 (1992) 8293-8298
70. Carroll M.P., Spivak J.L., McMahon M., Weich N., Rapp U.R., and May W.S. Erythropoietin induces Raf-1 activation and Raf-1 is required for erythropoietin-mediated proliferation. J Biol Chem 266 (1991) 14964-14969
71. Cutler R.L., Liu L., Damen J.E., and Krystal G. Multiple cytokines induce the tyrosine phosphorylation of Shc and its association with Grb2 in hemopoietic cells. J Biol Chem 268 (1993) 21463-21465
72. Shigematsu H., Iwasaki H., Otsuka T., Ohno Y., Arima F., and Niho Y. Role of the vav proto-oncogene product (Vav) in erythropoietin-mediated cell proliferation and phosphatidylinositol 3-kinase activity. J Biol Chem 272 (1997) 14334-14340
73. Hanazono Y., Chiba S., Sasaki K., Mano H., Yazaki Y., and Hirai H. Erythropoietin induces tyrosine phosphorylation and kinase activity of the c-fps/fes proto-oncogene product in human erythropoietin-responsive cells. Blood 81 (1993) 3193-3196
74. Tilbrook P.A., Ingley E., Williams J.H., Hibbs M.L., and Klinken S.P. Lyn tyrosine kinase is essential for erythropoietin-induced differentiation of J2E erythroid cells. EMBO J 16 (1997) 1610-1619
75. Odai H., Sasaki K., Iwamatsu A., et al. The proto-oncogene product c-Cbl becomes tyrosine phosphorylated by stimulation with GM-CSF or Epo and constitutively binds to the SH3 domain of Grb2/Ash in human hematopoietic cells. J Biol Chem 270 (1995) 10800-10805
76. Wilks A.F., Harpur A.G., Kurban R.R., Ralph S.J., Zurcher G., and Ziemiecki A. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol 11 (1991) 2057-2065
77. Sawyer S.T., and Penta K. Association of JAK2 and STAT5 with erythropoietin receptors. Role of receptor phosphorylation in erythropoietin signal transduction. J Biol Chem 271 (1996) 32430-32437
78. Chu J., Gui C.Y., Fan J., Tang X.D., and Qiao R.L. STAT1 is involved in signal transduction in the EPO induced HEL cells. Cell Res 8 (1998) 105-117
79. Silva M., Benito A., Sanz C., et al. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietindependent progenitor cell lines. J Biol Chem 274 (1999) 22165-22169
80. Ihle J.N. The Stat family in cytokine signaling. Curr Opin Cell Biol 13 (2001) 211-217
81. Millot G.A., Svinarchuk F., Lacout C., Vainchenker W., and Dumenil D. The granulocyte colony-stimulating factor receptor supports erythroid differentiation in the absence of the erythropoietin receptor or Stat5. Br J Haematol 112 (2001) 449-458
82. Mason J.M., Beattie B.K., Liu Q., Dumont D.J., and Barber D.L. The SH2 inositol 5-phosphatase Ship1 is recruited in an SH2-dependent manner to the erythropoietin receptor. J Biol Chem 275 (2000) 4398-4406
83. Xia K., Mukhopadhyay N.K., Inhorn R.C., et al. The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner. Proc Natl Acad Sci USA 93 (1996) 11681-11686
84. Chen C., and Sytkowski A.J. Erythropoietin activates two distinct signaling pathways required for the initiation and the elongation of c-myc. J Biol Chem 276 (2001) 38518-38526
85. Sui X., Krantz S.B., You M., and Zhao Z. Synergistic activation of MAP kinase (ERK1/2) by erythropoietin and stem cell factor is essential for expanded erythropoiesis. Blood 92 (1998) 1142-1149
86. Matsuzaki T., Aisaki K., Yamamura Y., Noda M., and Ikawa Y. Induction of erythroid differentiation by inhibition of Ras/ERK pathway in a friend murine leukemia cell line. Oncogene 19 (2000) 1500-1508
87. Miura Y., Miura O., Ihle J.N., and Aoki N. Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor. J Biol Chem 269 (1994) 29962-29969
88. Cardone M.H., Roy N., Stennicke H.R., et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 282 (1998) 1318-1321
89. Brunet A., Bonni A., Zigmond M.J., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 (1999) 857-868
90. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., and Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378 (1995) 785-789
91. Zimmermann S., and Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286 (1999) 1741-1744
92. He T.C., Zhuang H., Jiang N., Waterfield M.D., and Wojchowski D.M. Association of the p85 regulatory subunit of phosphatidylinositol 3-kinase with an essential erythropoietin receptor subdomain. Blood 82 (1993) 3530-3538
93. Mayeux P., Dusanter-Fourt I., Muller O., et al. Erythropoietin induces the association of phosphatidylinositol 3'-kinase with a tyrosine-phosphorylated protein complex containing the erythropoietin receptor. Eur J Biochem 216 (1993) 821-828
94. Damen J.E., Cutler R.L., Jiao H., Yi T., and Krystal G. Phosphorylation of tyrosine 503 in the erythropoietin receptor (EpR) is essential for binding the P85 subunit of phosphatidylinositol (PI) 3-kinase and for EpR-associated PI 3-kinase activity. J Biol Chem 270 (1995) 23402-23408
95. Verdier F., Chretien S., Billat C., Gisselbrecht S., Lacombe C., and Mayeux P. Erythropoietin induces the tyrosine phosphorylation of insulin receptor substrate-2. An alternate pathway for erythropoietin-induced phosphatidylinositol 3-kinase activation. J Biol Chem 272 (1997) 26173-26178
96. Wickrema A., Uddin S., Sharma A., et al. Engagement of Gab1 and Gab2 in erythropoietin signaling. J Biol Chem 274 (1999) 24469-24474
97. Jaster R., Bittorf T., and Brock J. Involvement of phosphatidylinositol 3-kinase in the mediation of erythropoietin-induced activation of p70S6k. Cell Signal 9 (1997) 175-179
98. Azzi A., Boscoboinik D., and Hensey C. The protein kinase C family. Eur J Biochem 208 (1992) 547-557
99. Newton A.C. Protein kinase C: structure, function, and regulation. J Biol Chem 270 (1995) 28495-28498
100. Newton A.C. Protein kinase C: ports of anchor in the cell. Curr Biol 6 (1996) 806-809
101. Newton A.C. Regulation of protein kinase C. Curr Opin Cell Biol 9 (1997) 161-167
102. Cheung J.Y., Elensky M.B., Brauneis U., et al. Ion channels in human erythroblasts. Modulation by erythropoietin. J Clin Invest 90 (1992) 1850-1856
103. Mason-Garcia M., Clejan S., Tou J.S., and Beckman B.S. Signal transduction by the erythropoietin receptor: evidence for the activation of phospholipases A2 and C. Am J Physiol 262 (1992) C1197-C1203
104. Boudot C., Petitfrere E., Kadri Z., et al. Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase C-gamma(2). J Biol Chem 274 (1999) 33966-33972
105. Spangler R., Bailey S.C., and Sytkowski A.J. Erythropoietin increases c-myc mRNA by a protein kinase C-dependent pathway. J Biol Chem 266 (1991) 681-684
106. Spangler R., and Sytkowski A.J. c-myc is an erythropoietin early response gene in normal erythroid cells: evidence for a protein kinase C-mediated signal. Blood 79 (1992) 52-57
107. Cai H., Smola U., Wixler V., et al. Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase. Mol Cell Biol 17 (1997) 732-741
108. Perletti G.P., Concari P., Brusaferri S., Marras E., Piccinini F., and Tashjian A.H. Protein kinase Cepsilon is oncogenic in colon epithelial cells by interaction with the ras signal transduction pathway. Oncogene 16 (1998) 3345-3348
109. Jenis D.M., Johnson C.S., and Furmanski P. Effects of inhibitors and activators of protein kinase C on late erythroid progenitor (CFU-e) colony formation in vitro. Int J Cell Cloning 7 (1989) 190-202
110. Myklebust J.H., Smeland E.B., Josefsen D., and Sioud M. Protein kinase C-alpha isoform is involved in erythropoietin-induced erythroid differentiation of CD34(+) progenitor cells from human bone marrow. Blood 95 (2000) 510-518
111. Patel H.R., Choi H.S., and Sytkowski A.J. Activation of two discrete signaling pathways by erythropoietin. J Biol Chem 267 (1992) 21300-21302
112. Patel H.R., and Sytkowski A.J. Erythropoietin activation of AP1 (Fos/Jun). Exp Hematol 23 (1995) 619-625
113. Li Y., Davis K.L., and Sytkowski A.J. Protein kinase C-epsilon is necessary for erythropoietin's up-regulation of c-myc and for factor-dependent DNA synthesis. Evidence for discrete signals for growth and differentiation. J Biol Chem 271 (1996) 27025-27030
114. Tsushima H., Urata Y., Miyazaki Y., et al. Human erythropoietin receptor increases GATA-2 and Bcl-xL by a protein kinase C-dependent pathway in human erythropoietin-dependent cell line AS-E2. Cell Growth Differ 8 (1997) 1317-1328
115. Zhang M.Y., Harhaj E.W., Bell L., Sun S.C., and Miller B.A. Bcl-3 expression and nuclear translocation are induced by granulocyte-macrophage colony-stimulating factor and erythropoietin in proliferating human erythroid precursors. Blood 92 (1998) 1225-1234
116. Chin H., Saito T., Arai A., et al. Erythropoietin and IL-3 induce tyrosine phosphorylation of CrkL and its association with Shc, SHP-2, and Cbl in hematopoietic cells. Biochem Biophys Res Commun 239 (1997) 412-417
117. Arai A., Kanda E., Nosaka Y., Miyasaka N., and Miura O. CrkL is recruited through its SH2 domain to the erythropoietin receptor and plays a role in Lyn-mediated receptor signaling. J Biol Chem 276 (2001) 33282-33290
118. Guillard C., Chretien S., Jockers R., Fichelson S., Mayeux P., and Duprez V. Coupling of heterotrimeric Gi proteins to the erythropoietin receptor. J Biol Chem 276 (2001) 2007-2014
119. Sasaki R., Masuda S., and Nagao M. Erythropoietin: multiple physiological functions and regulation of biosynthesis. Biosci Biotechnol Biochem 64 (2000) 1775-1793
120. Li F., Chong Z.Z., and Maiese K. Erythropoietin on a tightrope: balancing neuronal and vascular protection between intrinsic and extrinsic pathways. Neurosignals 13 (2004) 265-289
121. Jelkmann W., and Wagner K. Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol 83 (2004) 673-686
122. Tramontano A.F., Muniyappa R., Black A.D., et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 308 (2003) 990-994
123. Depping R., Kawakami K., Ocker H., et al. Expression of the erythropoietin receptor in human heart. J Thorac Cardiovasc Surg 130 (2005) 877-878
124. Parsa C.J., Matsumoto A., Kim J., et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112 (2003) 999-1007
125. Calvillo L., Latini R., Kajstura J., et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodelling. Proc Natl Acad Sci USA 100 (2003) 4802-4806
126. Moon C., Krawczyk M., Ahn D., et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 100 (2003) 11612-11617
127. Parsa C.J., Kim J., Riel R.U., et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 279 (2004) 20655-20662
128. Nishiya D., Omura T., Shimada K., et al. Effects of erythropoietin on cardiac remodeling after myocardial infarction. J Pharmacol Sci 101 (2006) 31-39
129. Anagnostou A., Lee E.S., Kessimian N., Levinson R., and Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 87 (1990) 5978-5982
130. Anagnostou A., Liu Z., Steiner M., et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 91 (1994) 3974-3978
131. Heeschen C., Aicher A., Lehmann R., et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102 (2003) 1340-1346
132. Bahlmann F.H., De Groot K., Spandau J.M., et al. Erythropoietin regulates endothelial progenitor cells. Blood 103 (2004) 921-926
133. Carlini R.G., Reyes A.A., and Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 47 (1995) 740-745
134. Ribatti D., Presta M., Vacca A., et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93 (1999) 2627-2636
135. Carlini R.G., Alonzo E.J., Dominguez J., et al. Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 55 (1999) 546-553
136. 2+ mobilization and contraction in rat mesangial and aortic smooth muscle cultures. Exp Hematol 24 (1996) 392-397
137. Heidenreich S., Rahn K.H., and Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 39 (1991) 259-265
138. Gogusev J., Zhu D.L., Herembert T., Ammarguellat F., Marche P., and Drueke T. Effect of erythropoietin on DNA synthesis, proto-oncogene expression and phospholipase C activity in rat vascular smooth muscle cells. Biochem Biophys Res Commun 199 (1994) 977-983
139. Akimoto T., Kusano E., Inaba T., et al. Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int 58 (2000) 269-282
140. Ammarguellat F., Llovera M., Kelly P.A., and Goffin V. Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells. Biochem Biophys Res Commun 284 (2001) 1031-1038
141. Westenfelder C., Biddle D.L., and Baranowski R.L. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 55 (1999) 808-820
142. Vesey D.A., Cheung C., Pat B., Endre Z., Gobe G., and Johnson D.W. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 19 (2004) 348-355
143. Sharples E.J., Patel N., Brown P., et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15 (2004) 2115-2124
144. Brier M.E., Bunke C.M., Lathon P.V., and Aronoff G.R. Erythropoietin-induced antinatriuresis mediated by angiotensin II in perfused kidneys. J Am Soc Nephrol 3 (1993) 1583-1590
145. Yang C.W., Li C., Jung J.Y., et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 17 (2003) 1754-1755
146. Imamura R., Moriyama T., Isaka Y., et al. Erythropoietin protects the kidneys against ischemia reperfusion injury by activating hypoxia inducible factor-1alpha. Transplantation 83 (2007) 1371-1379
147. Vaziri N.D., Zhou X.J., and Liao S.Y. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol 266 (1994) F360-F366
148. Digicaylioglu M., Bichet S., Marti H.H., et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA 92 (1995) 3717-3720
149. Yamaji R., Okada T., Moriya M., et al. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 239 (1996) 494-500
150. Campana W.M., and Myers R.R. Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury. FASEB J 15 (2001) 1804-1806
151. Noguchi C.T., Asavaritikrai P., Teng R., and Jia Y. Role of erythropoietin in the brain. Crit Rev Oncol Hematol 64 (2007) 159-171
152. Studer L., Csete M., Lee S.H., et al. Enhanced proliferation, survival, and dopaminergic differentation of CNS precursors in lowered oxygen. J Neurosci 20 (2000) 7377-7383
153. Shingo T., Sorokan S.T., Shimazaki T., and Weiss S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 21 (2001) 9733-9743
154. Konishi Y., Chui D.H., Hirose H., Kunishita T., and Tabira T. Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res 609 (1993) 29-35
155. Sakanaka M., Wen T.C., Matsuda S., et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 95 (1998) 4635-4640
156. Sadamoto Y., Igase K., Sakanaka M., et al. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun 253 (1998) 26-32
157. Wen T.C., Sadamoto Y., Tanaka I., et al. Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL expression. J Neurosci Res 67 (2002) 795-803
158. Chong Z.Z., Kang J.Q., and Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 106 (2003) 2973-2979
159. Brines M.L., Ghezzi P., Keenan S., et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97 (2000) 10526-10531
160. Siren A.L., Fratelli M., Brines M., et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 98 (2001) 4044-4049
161. Buemi M., Grasso G., Corica F., et al. In vivo evidence that erythropoietin has a neuroprotective effect during subarachnoid hemorrhage. Eur J Pharmacol 392 (2000) 31-34
162. Villa P., Bigini P., Mennini T., et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 198 (2003) 971-975
163. Leist M., Ghezzi P., Grasso G., et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305 (2004) 239-242
164. Brines M., Grasso G., Fiordaliso F., et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 101 (2004) 14907-14912
165. Osterborg A., Aapro M., Cornes P., Haselbeck A., Hayward C.R., and Jelkmann W. Preclinical studies of erythropoietin receptor expression in tumour cells: Impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 43 (2007) 510-519
166. Winter S.C., Shah K.A., Campo L., et al. Relation of erythropoietin and erythropoietin receptor expression to hypoxia and anemia in head and neck squamous cell carcinoma. Clin Cancer Res 11 (2005) 7614-7620
167. Arcasoy M.O., Amin K., Vollmer R.T., Jiang X., Demark-Wahnefried W., and Haroon Z.A. Erythropoietin and erythropoietin receptor expression in human prostate cancer. Mod Pathol 18 (2005) 421-430
168. Dagnon K., Pacary E., Commo F., et al. Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res 11 (2005) 993-999
169. Lee Y.S., Vortmeyer A.O., Lubensky I.A., et al. Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. Clin Cancer Res 11 (2005) 1059-1064
170. Yates C.M., Patel A., Oakley K., Helms A., Tuttle R.M., and Francis G.L. Erythropoietin in thyroid cancer. J Endocrinol Invest 29 (2006) 320-329
171. Sinclair A., Rogers N., Busse L., et al. Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Brit J Cancer 98 (2008) 1059-1067
172. Dillard D.G., Venkatraman G., Cohen C., Delgaudio J., Gal A.A., and Mattox D.E. Immunolocalization of erythropoietin and erythropoietin receptor in vestibular schwannoma. Acta Otolaryngol 121 (2001) 149-152
173. Arcasoy M.O., Amin K., Karayal A.F., et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 82 (2002) 911-918
174. Acs G., Zhang P.J., Rebbeck T.R., Acs P., and Verma A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 95 (2002) 969-981
175. Acs G., Acs P., Beckwith S.M., et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61 (2001) 3561-3565
176. Acs G., Zhang P.J., McGrath C.M., et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 162 (2003) 1789-1806
177. Batra S., Perelman N., Luck L.R., Shimada H., and Malik P. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 83 (2003) 1477-1487
178. Arcasoy M.O., Jiang X., and Haroon Z.A. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun 307 (2003) 999-1007
179. Acs G., Xu X., Chu C., Acs P., and Verma A. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 100 (2004) 2376-2386
180. Hoogsteen I.J., Peeters W.J., Marres H.A., et al. Erythropoietin receptor is not a surrogate marker for tumor hypoxia and does not correlate with survival in head and neck squamous cell carcinomas. Radiother Oncol 76 (2005) 213-218
181. Arcasoy M.O., Amin K., Chou S.C., Haroon Z.A., Varia M., and Raleigh J.A. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin Cancer Res 11 (2005) 20-27
182. Henke M., Mattern D., Pepe M., et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J Clin Oncol 24 (2006) 4708-4713
183. Leo C., Horn L.C., Rauscher C., et al. Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis. Clin Cancer Res 12 (2006) 6894-6900
184. Diensthuber M., Ilner T., Rodt T., et al. Erythropoietin and erythropoietin receptor expression investibular Schwannoma: potential role in tumor progression. Otol Neurotol 28 (2007) 559-565
185. Ribatti D., Marzullo A., Gentile A., et al. Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology 50 (2007) 591-596
186. Ribatti D., Poliani P.L., Longo V., Mangieri D., Nico B., and Vacca A. Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathology 50 (2007) 636-641
187. Elliott S., Sinclair A.M., and Begley C.G. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 107 (2006) 1892-1895
188. Brown W.M., Maxwell P., Graham A.N.J., et al. Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells 25 (2007) 718-722
189. Laugsch M., Metzen E., Svensson T., Depping R., and Jelkmann W. Lack of functional erythropoietin receptors of cancer cell lines. Int J Cancer 122 (2008) 1005-1011
190. Della R.F., Cucciolla V., Borriello A., Oliva A., and Perrotta S. Erythropoietin receptors on cancer cells: a still open question. J Clin Oncol 25 (2007) 1812-1813
191. Verdier F., Gomez S., Lacombe C., and Mayeux P. Selected anti-Epo receptor antibodies predict Epo receptor expression. Blood 108 (2006) 1106
192. Kirkeby A., van B.J., Nielsen J., Leist M., and Helboe L. Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor. J Neurosci Methods 164 (2007) 50-58
193. Ohigashi T., Yoshioka K., and Fisher J.W. Autocrine regulation of erythropoietin gene expression in human hepatocellular carcinoma cells. Life Sci 58 (1996) 421-427
194. Selzer E., Wacheck V., Kodym R., et al. Erythropoietin receptor expression in human melanoma cells. Melanoma Res 10 (2000) 421-426
195. Westenfelder C., and Baranowski R.L. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58 (2000) 647-657
196. Yasuda Y., Musha T., Tanaka H., et al. Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 84 (2001) 836-843
197. Westphal G., Niederberger E., Blum C., et al. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 88 (2002) 150-159
198. Yasuda Y., Fujita Y., Matsuo T., et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24 (2003) 1021-1029
199. Kumar S.M., Acs G., Fang D., Herlyn M., Elder D.E., and Xu X. Functional erythropoietin autocrine loop in melanoma. Am J Pathol 166 (2005) 823-830
200. Mohyeldin A., Lu H., Dalgard C., et al. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 7 (2005) 537-543
201. Jeong J.-Y., Feldman L., Solar P., Szenajch J., and Sytkowski A.J. Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells. Int J Cancer 122 (2008) 274-280
202. Lester R.D., Jo M., Campana W.M., and Gonias S.L. Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem 280 (2005) 39273-39277
203. Acs G., Chen M., Xu X., Acs P., Verma A., and Koch C.J. Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells. Cancer Lett 214 (2004) 243-251
204. Sinclair A.M., Todd M.D., Forsythe K., Knox S.J., Elliott S., and Begley C.G. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 110 (2007) 477-488
205. Hale S.A., Wong C., and Lounsbury K.M. Erythropoietin disrupts hypoxia-inducible factor signaling ovarian cancer cells. Gynecol Oncol 100 (2006) 14-19
206. LaMontagne K.R., Butler J., Marshall D.J., et al. Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 5 (2006) 347-355
207. Berdel W.E., Oberberg D., Reufi B., and Thiel E. Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. Ann Hematol 63 (1991) 5-8
208. Mundt D., Berger M.R., and Bode G. Effect of recombinant human erythropoietin on the growth of human tumor cell lines in vitro. Micro-titertec-tetrazolium assay. Arzneimittelforschung 42 (1992) 92-95
209. Rosti V., Pedrazzoli P., Ponchio L., et al. Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. Haematologica 78 (1993) 208-212
210. Wollman Y., Westphal G., Blum M., et al. The effect of human recombinant erythropoietin on the growth of a human neuroblastoma cell line. Life Sci 59 (1996) 315-322
211. Grossi A., Vannucchi A.M., Bacci P., et al. Erythropoietin upregulates the expression of its own receptor in TF-1 cell line. Leuk Res 22 (1998) 145-151
212. Shannon A.M., Bouchier-Hayes D.J., Condron C.M., and Toomey D. Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma. Br J Cancer 93 (2005) 224-232
213. Tovari J., Gilly R., Raso E., et al. Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models. Cancer Res 65 (2005) 7186-7193
214. Jelkmann W. Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin preparations. In: Nowrousian M.R. (Ed). Recombinant human erythropoietin (rhEPO) in clinical oncology. 2nd ed. (2008), Springer, Wien New York 407-431
215. Feldman L., Wang Y., Rhim J.S., Bhattacharya N., Loda M., and Sytkowski A.J. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 66 (2006) 135-145
216. Dunlop E.A., Percy M.J., Boland M.P., Maxwell A.P., and Lappin T.R. Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin. Neurodegen Dis 3 (2006) 94-100
217. Dunlop E.A., Maxwell A.P., and Lappin T.R. Impaired downregulation following erythropoietin receptor activation in non-small cell lung carcinoma. Stem Cells 25 (2007) 380-384
218. Spyridonidis A., Bernhardt W., Behringer D., et al. Proliferation and survival of mammary carcinoma cells are influenced by culture conditions used for ex vivo expansion of CD34(+) blood progenitor cells. Blood 93 (1999) 746-755
219. Um M., and Lodish H.F. Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways. J Biol Chem 281 (2006) 5648-5656
220. Bauer E., Danhauser-Riedl S., De Riese W., et al. Effects of recombinant human erythropoietin on clonogenic growth of primary human tumor specimens in vivo. Onkologie 15 (1992) 254-258
221. Kokhaei P., Abdalla A.O., Hansson L., et al. Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin Cancer Res 13 (2007) 3536-3544
222. Liu W.M., Powles T., Shamash J., Propper D., Oliver T., and Joel S. Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene 23 (2004) 981-990
223. Gewirtz D.A., Di X., Walker T.D., and Sawyer S.T. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs. Clin Cancer Res 12 (2006) 2232-2238
224. Carvalho G., Lefaucheur C., Cherbonnier C., et al. Chemosensitization by erythropoietin through inhibition of the NF-kappaB rescue pathway. Oncogene 24 (2005) 737-745
225. Belenkov A.I., Shenouda G., Rizhevskaya E., et al. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther 3 (2004) 1525-1532
226. Hanazono Y., Sasaki K., Nitta H., Yazaki Y., and Hirai H. Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF receptor. Biochem Biophys Res Commun 208 (1995) 1060-1066
227. Um M., Gross A.W., and Lodish H.F. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal 19 (2007) 634-645
228. Solar P., Feldman L., Jeong J.-Y., Busingye J.R., and Sytkowski A.J. Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype. Int J Cancer 122 (2008) 281-288
229. Hardee M.E., Cao Y., Fu P., et al. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE 2 (2007) e549
230. Blackwell K.L., Kirkpatrick J.P., Snyder S.A., et al. Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin. Cancer Res 63 (2003) 6162-6165
231. Thews O., Kelleher D.K., and Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 61 (2001) 1358-1361
232. Silver D.F., and Piver M.S. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol 73 (1999) 280-284
233. Sigounas G., Sallah S., and Sigounas V.Y. Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model. Cancer Lett 214 (2004) 171-179
234. Stuben G., Thews O., Pottgen C., Knuhmann K., Vaupel P., and Stuschke M. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 127 (2001) 346-350
235. Stuben G., Pottgen C., Knuhmann K., et al. Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 55 (2003) 1358-1362
236. Thews O., Koenig R., Kelleher D.K., Kutzner J., and Vaupel P. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 78 (1998) 752-756
237. Hardee M.E., Kirkpatrick J.P., Shan S., et al. Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. Br J Cancer 93 (2005) 1350-1355
238. Mittelman M., Neumann D., Peled A., Kanter P., and Haran-Ghera N. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 98 (2001) 5181-5186
239. Katz O., Barzilay E., Skaat A., Herman A., Mittelman M., and Neumann D. Erythropoietin induced tumour mass reduction in murine lymphoproliferative models. Acta Haematol 114 (2005) 177-179
240. Katz O., Gil L., Lifshitz L., et al. Erythropoietin enhances immune responses in mice. Eur J Immunol 37 (2007) 1584-1593
241. Kanzaki M., Soda K., Gin P.T., Kai T., Konishi F., and Kawakami M. Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine. Cytokine 32 (2005) 234-239
242. Bianchi R., Gilardini A., Rodriguez-Menendez V., et al. Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. Eur J Cancer 43 (2007) 710-717
243. Efthimiadou A., Pagonopoulou O., Lambropoulou M., Papadopoulos N., and Nikolettos N.K. Erythropoietin enhances angiogenesis in an experimental cyclosporine a-induced nephrotoxicity model in the rat. Clin Exp Pharmacol Physiol 34 (2007) 866-869
244. Li L., Takemura G., Li Y., et al. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 113 (2006) 535-543
245. Bodo E., Kromminga A., Funk W., et al. Human hair follicles are an extrarenal source and a nonhematopoietic target of erythropoietin. FASEB J 21 (2007) 3346-3354
246. Groopman J.E., and Itri L.M. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91 (1999) 1616-1634
247. Knight K., Wade S., and Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 116 (2004) 11S-26S
248. Ludwig H., Van B.S., Barrett-Lee P., et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40 (2004) 2293-2306
249. Ludwig H., and Strasser K. Symptomatology of anemia. Semin Oncol 28 2, Suppl. 8 (2001) 7-14
250. Caro J.J., Salas M., Ward A., and Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91 (2001) 2214-2221
251. Goodnough L.T. Risks of blood transfusion. Anesthesiol Clin North America 23 (2005) 241-252
252. Jelkmann W. Recombinant EPO production-points the nephrologist should know. Nephrol Dial Transplant 22 (2007) 2749-2753
253. Halstenson C.E., Macres M., Katz S.A., et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 50 (1991) 702-712
254. Glaspy J., Vadhan-Raj S., Patel R., et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol 24 (2006) 2290-2297
255. European Medicines Agency. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues - guidance on similar medicinal products containing recombinant erythropoietins. http://www.emea.europa.eu/pdfs/human/biosimilar/9452605en.pdf. Accessed August 8, 2007.
256. Ortho Biotech. Procrit_Full prescribing information. http://www.procrit.com/procrit/#boxed.
257. Cazzola M., Beguin Y., Kloczko J., Spicka I., and Coiffier B. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 122 (2003) 386-393
258. Amgen Inc. Aranesp prescribing information. http://www.aranesp.com/#boxed_warning.
259. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - v.1.2008. Cancer- and Treatment-Related Anemia. http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf.
260. Seidenfeld J., Piper M., Flamm C., et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93 (2001) 1204-1214
261. Bottomley A., Thomas R., van S.K., Flechtner H., and Djulbegovic B. Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?. Lancet Oncol 3 (2002) 145-153
262. Clark O., Adams J.R., Bennett C.L., and Djulbegovic B. Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer 2 (2002) 23
263. Bohlius J., Wilson J., Seidenfeld J., et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98 (2006) 708-714
264. Wilson J., Yao G.L., Raftery J., et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 11 (2007) 1-220
265. Shehata N, Walker I, Meyer R, Haynes AE, Imrie K, Cancer Care Ontario's Program in Evidence-Based Care's Systematic Disease Site Group. Treatment for anemia with erythropoietic agents in patients with non-myeloid hematological malignancies: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2007; Evidence-based series; no. 6-12. http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=10583&nbr=5525-47k-.
266. Bennett C.L., Luminari S., Nissenson A.R., et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 351 (2004) 1403-1408
267. Leyland-Jones B., Semiglazov V., Pawlicki M., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23 (2005) 5960-5972
268. Henke M., Laszing R., Rübe C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
269. Rosenzweig M.Q., Bender C.M., Lucke J.P., Yasko J.M., and Brufsky A.M. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 27 (2004) 185-190
270. Littlewood T.J., Bajetta E., Nortier J.W., Vercammen E., and Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19 (2001) 2865-2874
271. Antonadou D., Cardamakis E., Puglisi M., Malamos N., and Throuvalas N. Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. Final results of a randomized phase III study. Eur J Cancer 37 Suppl. 6 (2001) S144
272. Blohmer J.U., Wurschmidt F., Petry U., Weise G., Sehouli J., and Kimming R. Results with sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for patients with high-risk cervical cancer: Results of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study. Ann Oncol 15 Suppl. 3 (2004) [abstract]
273. Bohlius J., Langensiepen S., Schwarzer G., et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97 (2005) 489-498
274. Leyland-Jones B., and BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4 (2003) 459-460
275. EPO-CAN-15 in: Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy: Hearings Before the SubComm. on Oncologic Drugs Advisory Committee of the House Comm. on Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (May 4, 2004).
276. GOG-191 in: Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy: Hearings Before the SubComm. on Oncologic Drugs Advisory Committee of the House Comm. on Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (May 4, 2004).
277. Vadhan-Raj S., Skibber J.M., Crane C., et al. Randomized, double-blind, placebo-controlled trial of epoetin alfa (Procrit) in patients with rectal and gastric cancer undergoing chemo-radiotherapy (CT/RT) followed by surgery: early termination of the trial due to increased incidence of thrombo-embolic events (TEE). Blood 104 (2004) 797a [abstract]
278. Saftety concerns associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the treatment of anemia associated with cancer chemotherapy: Hearings Before the SubComm. on Oncologic Drugs Advisory Committee of the House Comm. on Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (2004).
279. Amgen 2001 0103 in: Continuing Reassessment of the Risks of Erythropoiesis-Stimulating Agents (ESAs) Administered for the Treatment of Anemia Associated with Cancer Chemotherapy: of the House Comm. on Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (May 10, 2007).
280. Amgen 2000 0161 in: Continuing Reassessment of the Risks of Erythropoiesis-Stimulating Agents (ESAs) Administered for the Treatment of Anemia Associated with Cancer Chemotherapy: of the House Comm. on Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (May 10, 2007).
281. Hedenus M., Adriansson M., San Miguel J., et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122 (2003) 394-403
282. EPO-CAN-20 in: Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy: Hearings Before the SubComm. on Oncologic Drugs Advisory Committee of the House Comm. on Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (May 4, 2004).
283. ®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC)-the Danish Head and Neck Cancer Group DAHANCA 10. Eur J Cancer Suppl 5 No. 6 (2007) 7
284. Machtay M., Pajak T.F., Suntharalingam M., et al., Radiation Therapy Oncology Group (RTOG 99-03). Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys 69 (2007) 1008-1017
285. Machtay M., Pajak T., Suntharalingam M., Hershock D., Stripp D.C., and Cmelak A. Definitive radiotherapy ± erythropoietin for squamous cell carcinoma of the head and neck: preliminary report of RTOG 99-03. Int J Radiat Oncol Biol Phys 60 Suppl. 1 (2004) S132
286. EPO GBR-07 in: Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy: Hearings Before the SubComm. on Oncologic Drugs Advisory Committee of the House Comm. on Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (May 4, 2004).
287. Rosen F.R., Haraf D.J., Kies M.S., et al. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res 9 (2003) 1689-1697
288. Chang J., Couture F., Young S., McWatters K.L., and Lau C.Y. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 23 (2005) 2597-2605
289. EPO-CAN-17 in: Continuing Reassessment of the Risks of Erythropoiesis-Stimulating Agents (ESAs) Administered for the Treatment of Anemia Associated with Cancer Chemotherapy: Hearings Before the SubComm. on Oncology Drugs Advisory Committee of the House Comm. on Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (May 10, 2007).
290. Moebus V., Lueck H., Thomssen C., Harbeck N., Nitz U., and Kreienberg R. The impact of epoetin alpha on anemia, red blood cell (RBC) transfusion, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial). J Clin Oncol 25 (2007) 18S [abstract]
291. Aapro M., Leonard R.C., Barnadas A., et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol 26 (2008) 592-598
292. Wright J.R., Ung Y.C., Julian J.A., et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25 (2007) 1027-1032
293. Vansteenkiste J., Pirker R., Massuti B., et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94 (2002) 1211-1220
294. N93 004 in: Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy: Hearings Before the SubComm. on Oncologic Drugs Advisiory Committee of the House Comm. on Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (May 4, 2004).
295. Grote T., Yeilding A.L., Castillo R., et al. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 23 (2005) 9377-9386
296. Amgen 2001 0145 in: Continuing Reassessment of the Risks of Erythropoiesis-Stimulating Agents (ESAs) Administered for the Treatment of Anemia Associated with Cancer Chemotherapy: of the House Comm. on Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (May 10, 2007).
297. Continuing Reassessment of the Risks of Erythropoiesis-Stimulating Agents (ESAs) Administered for the Treatment of Anemia Associated with Cancer Chemotherapy: of the House Comm. on Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (May 10, 2007).
298. Cazzola M., Messinger D., Battistel V., et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 86 (1995) 4446-4453
299. Osterborg A., Boogaerts M.A., Cimino R., et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma-a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 87 (1996) 2675-2682
300. Osterborg A., Brandberg Y., Molostova V., et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 20 (2002) 2486-2494
301. Smith Jr. R.E., Aapro M.S., Ludwig H., et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 26 (2008) 1040-1050
302. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 29A Suppl. 2 (1993) S2-S8
303. Smith R.E., Tchekmedyian N.S., Chan D., et al. A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 88 (2003) 1851-1858
304. Charu V., Belani C.P., Gill A.N., et al. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial. Oncologist 12 (2007) 727-737
305. Gordon D.H., Nichols G., Ben-Jacob A., Lam H., Lillie T., and Miller C. Treating anemia of cancer with Darbepoetin alfa administered every 4 weeks: final results from a phase 2, randomized, double-blind, placebo-controlled study in cancer patients not receiving chemotherapy and/or radiotherapy. Blood 108 (2006) 11 [abstract]
306. Mystakidou K., Kalaidopoulou O., Katsouda E., et al. Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment. Anticancer Res 25 (2005) 3495-3500
307. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
308. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
309. Rizzo J.D., Somerfield M.R., Hagerty K.L., et al., American Society of Clinical Oncology; American Society of Hematology. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 26 (2008) 132-149
310. Wun T., Law L., Harvey D., Sieracki B., Scudder S.A., and Ryu J.K. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 98 (2003) 1514-1520
311. Stohlawetz P.J., Dzirlo L., Hergovich N., et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 95 (2000) 2983-2989